Oppenheimer Downgrades Pliant Therapeutics (PLRX) to Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Altria Group (MO) Misses Q2 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
JPMorgan Downgrades Pliant Therapeutics (PLRX) to Neutral
February 10, 2025 8:58 AM ESTJPMorgan analyst Eric Joseph downgraded Pliant Therapeutics (NASDAQ: PLRX) from Overweight to Neutral.
The analyst comments "We are downgrading PLRX shares from Overweight to Neutral on the back of the voluntary pause of the BEACON-IPF (bexotegrast in IPF) trial announced Friday... More
H.C. Wainwright Downgrades Pliant Therapeutics (PLRX) to Neutral
February 10, 2025 6:04 AM ESTH.C. Wainwright analyst Ed Arce downgraded Pliant Therapeutics (NASDAQ: PLRX) from Buy to Neutral.
The analyst comments "Our Take. This could turn out to be nothing, or it could spell the end for bexotegrast, if its a serious toxicity event(s) deemed likely due to study drug. Immediately following Friday's press... More
Pliant Therapeutics Inc. (PLRX) call put ratio 7.1 calls to 1 put into pauses enrollment, dosing in BEACON-IPF Phase 2b trial
February 10, 2025 5:13 AM ESTPliant Therapeutics Inc. (NASDAQ: PLRX) 30-day option implied volatility is at 105; compared to its 52-week range of 56 to 118. Call put ratio 7.1 calls to 1 put with a focus on February 10 calls into pauses enrollment, dosing in BEACON-IPF Phase 2b trial.
... MoreRBC Capital Downgrades Pliant Therapeutics (PLRX) to Sector Perform
February 10, 2025 5:09 AM ESTRBC Capital analyst Brian Abrahams downgraded Pliant Therapeutics (NASDAQ: PLRX) from Outperform to Sector Perform with a price target of $4.00 (from $45.00).
For an analyst ratings summary and ratings history on Pliant Therapeutics click here. For more ratings news on Pliant Therapeutics click here.
Shares of Pliant Therapeutics closed at $7.79 yesterday.
... MoreWells Fargo Downgrades Pliant Therapeutics (PLRX) to Equal Weight
February 10, 2025 3:19 AM ESTWells Fargo analyst Tiago Fauth downgraded Pliant Therapeutics (NASDAQ: PLRX) from Overweight to Equal Weight with a price target of $4.00 (from $41.00).
For an analyst ratings summary and ratings history on Pliant Therapeutics click here. For more ratings news on Pliant Therapeutics click here.
Shares of Pliant Therapeutics closed at $7.79 yesterday.
... MoreCiti Downgrades Pliant Therapeutics (PLRX) to Neutral
February 10, 2025 3:15 AM ESTCiti analyst David Lebowitz downgraded Pliant Therapeutics (NASDAQ: PLRX) from Buy to Neutral with a price target of $4.00 (from $40.00).
The analyst comments: "After the close on Friday, Pliant announced it has voluntarily paused enrollment and dosing for the BEACON-IPF Ph2b/3 study which examines... More
Pliant Therapeutics Inc. (PLRX) Provides Update on BEACON-IPF
February 7, 2025 5:01 PM ESTPliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendations by the trials independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). Patients currently enrolled in BEACON-IPF will remain in the trial.
Enrollment and dosing have been paused while data is reviewed to understand the DSMBs rationale for their recommendation. Blinding of the study will be maintained to preserve trial integrity. The Company has informed... More
